Welcome to our dedicated page for TAURIGA SCIENCES news (Ticker: TAUG), a resource for investors and traders seeking the latest updates and insights on TAURIGA SCIENCES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TAURIGA SCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TAURIGA SCIENCES's position in the market.
Tauriga Sciences (TAUG) has launched its Tauri-Gum™ product line in the United Kingdom. The company has also hired a full-time salesperson in London to drive sales growth in the region. Tauriga anticipates significant sales increases for the remainder of 2021 and beyond. Their Tauri-Gum™ products, which include various CBD and CBG infused flavors, aim to capitalize on the growing edibles market. The company is also working on a pharmaceutical-grade version of Tauri-Gum™ to aid nausea for chemotherapy patients, having filed a non-provisional patent application.
Tauriga Sciences (TAUG) announced on July 14, 2021, that it has begun generating revenue through sales on Amazon.com, receiving multiple customer orders. The company is actively expanding its product listings on the platform, aiming for increased sales in the first fiscal quarter of 2022. Additionally, Tauriga's Vitamin D3 Infused Tauri-Gum was featured in WholeFoods Magazine, highlighting its market presence. The company's product line includes various infused chewing gums, and it is also pursuing pharmaceutical development for a nausea-regulating version of Tauri-Gum.
Tauriga Sciences, Inc. (TAUG) has announced the launch of its new topical products: Tauri-Sun™ CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip Balm. Both products feature a 30 SPF and are designed for easy application. The sunscreen contains 200mg of CBD isolate and is hypoallergenic and reef-friendly. In addition, the company has listed its Tauri-Pet™ dog treat on Amazon and plans to expand its product lineup. The firm continues to grow its retail and E-Commerce presence, as well as its pharmaceutical development initiatives.
Tauriga Sciences, Inc. (TAUG) has announced that its products, particularly Tauri-Gum™, are now available for sale on Amazon, the largest online retailer. The company is in the process of listing additional products, which may involve packaging modifications. Approval has been received for Amazon Brand Registry for Tauri-Gum™, aiming to enhance sales and protect trademarks. Tauriga focuses on CBD and CBG products with a broad retail and e-commerce strategy. It also has plans for a pharmaceutical-grade version of Tauri-Gum™ targeting chemotherapy-related nausea.
Tauriga Sciences, Inc. (OTCQB: TAUG) announced the launch of two limited-edition Tauri-Gum™ products in collaboration with Think BIG, LLC. The flavors, Honey Lemon and Mint, are set to be available for retail and wholesale on August 1, 2021, with inventory available from July 19, 2021. This partnership aims to create innovative cannabinoid products and includes a substantial marketing effort starting in September 2021. The Tauri-Gum™ products are Kosher, Halal, Vegan, and Non-GMO, reinforcing the company's commitment to quality and health.
Tauriga Sciences, Inc. (OTCQB: TAUG) announced that its Brand Registry Application for Tauri-Gum™ has been approved by Amazon. This approval allows the company to protect its trademarks and enhance customer experience. Tauriga is in the process of listing its products on Amazon, leveraging its existing E-Commerce fulfillment infrastructure. The company also develops pharmaceutical-grade Tauri-Gum™ aimed at nausea regulation for chemotherapy patients and has filed a non-provisional patent application for its medicated compositions.
Tauriga Sciences (TAUG) has partnered with No Excuses Enterprises, founded by NFL Hall of Famer Ray Lewis, focusing on professional sports to enhance Tauri-Gum™ brand visibility. The collaboration aims to innovate product formulations and leverage synergies for growth. The company is set to launch its enhanced Tauri-Gum™ product line, now including 9 distinct SKUs. CEO Seth M. Shaw highlights the partnership as a significant opportunity to elevate the brand and its market presence. The company specializes in CBD and CBG edibles through its E-Commerce platform and retail distribution.
Tauriga Sciences, Inc. (TAUG) has appointed Dr. Craig Loucks to its Advisory Board. Dr. Loucks, an experienced orthopedic surgeon, aims to enhance Tauri-Gum™ product sales in Colorado through medical practices and dispensaries. He is also set to support the company's pharmaceutical development initiatives. Tauriga focuses on CBD and CBG infused products, with Tauri-Gum™ being its flagship, offering a variety of flavors and health benefits. The firm is committed to expanding its presence in both retail and e-commerce sectors.
Tauriga Sciences (TAUG) has secured approval to become a Registered Vendor at Miami International Airport (MIA) for selling its Tauri-Gum™ product line. The Company is partnering with a South Florida distribution firm to target select U.S. airports. With the upcoming launch of an enhanced Tauri-Gum™ product line (9 SKUs), Tauriga aims to capitalize on strong sales trends in airport retail. Additionally, an updated Product Catalogue with wholesale pricing has been completed, and meetings are scheduled with potential national buyers and distributors.
Tauriga Sciences (OTCQB: TAUG) announced the launch of its Super Deluxe Rainbow Pack, featuring nine Tauri-Gum SKUs and a 10th Mystery Flavor. The company will donate $3 from each pack to charity, aiming to boost future e-commerce sales. The original Rainbow Pack, launched in September 2020, has been successful in the market. Pre-orders will commence this week on the company's e-commerce website. Additionally, Tauriga is developing a pharmaceutical-grade Tauri-Gum for chemotherapy-related nausea, having filed a non-provisional patent application.
FAQ
What is the market cap of TAURIGA SCIENCES (TAUG)?
